Menstrual tampons and vaginal pessaries: regulation of intravaginal medical devices by the US FDA.

IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Frontiers in reproductive health Pub Date : 2023-09-19 eCollection Date: 2023-01-01 DOI:10.3389/frph.2023.1224421
Colin M Pollard
{"title":"Menstrual tampons and vaginal pessaries: regulation of intravaginal medical devices by the US FDA.","authors":"Colin M Pollard","doi":"10.3389/frph.2023.1224421","DOIUrl":null,"url":null,"abstract":"<p><p>Catamenial products like menstrual tampons for managing menses and vaginal pessaries for managing urinary incontinence and uterine prolapse are products that can be inserted and removed from the vagina repeatedly over a woman's lifetime. In the United States (US), these products are considered to be medical devices and are regulated by the Center for Devices & Radiological Health (CDRH) of the Food and Drug Administration (FDA). As such, they are subject to both premarket and postmarket regulatory controls. Both tampons and pessaries have a long history of safe and effective use, and FDA applies a risk-based approach to both premarket entry as well as continued postmarket regulatory controls. Practicing clinicians are often the initial source of ideas for medical device improvements. This article is intended to help such clinicians to understand the regulatory challenges faced by development teams who seek to introduce these kinds of products to the US market. It explains FDA's risk-based classification of medical devices and the 510(k) premarket notification as the primary regulatory mechanism for market entry. It also highlights key FDA guidance documents and encourages early engagement with FDA when appropriate.</p>","PeriodicalId":73103,"journal":{"name":"Frontiers in reproductive health","volume":"5 ","pages":"1224421"},"PeriodicalIF":2.3000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546303/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in reproductive health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frph.2023.1224421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Catamenial products like menstrual tampons for managing menses and vaginal pessaries for managing urinary incontinence and uterine prolapse are products that can be inserted and removed from the vagina repeatedly over a woman's lifetime. In the United States (US), these products are considered to be medical devices and are regulated by the Center for Devices & Radiological Health (CDRH) of the Food and Drug Administration (FDA). As such, they are subject to both premarket and postmarket regulatory controls. Both tampons and pessaries have a long history of safe and effective use, and FDA applies a risk-based approach to both premarket entry as well as continued postmarket regulatory controls. Practicing clinicians are often the initial source of ideas for medical device improvements. This article is intended to help such clinicians to understand the regulatory challenges faced by development teams who seek to introduce these kinds of products to the US market. It explains FDA's risk-based classification of medical devices and the 510(k) premarket notification as the primary regulatory mechanism for market entry. It also highlights key FDA guidance documents and encourages early engagement with FDA when appropriate.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
月经卫生棉条和阴道托:美国食品药品监督管理局对阴道内医疗器械的监管。
用于管理月经的月经棉条和用于管理尿失禁和子宫脱垂的阴道托等月经用品是可以在女性一生中反复从阴道插入和取出的产品。在美国,这些产品被视为医疗器械,由美国食品药品监督管理局的器械与放射卫生中心(CDRH)监管。因此,它们同时受到上市前和上市后监管控制。卫生棉条和子宫托都有着长期安全有效的使用历史,美国食品药品监督管理局对上市前进入和持续的上市后监管控制都采用了基于风险的方法。执业临床医生通常是医疗器械改进的最初想法来源。本文旨在帮助这些临床医生了解寻求将这类产品引入美国市场的开发团队所面临的监管挑战。它解释了美国食品药品监督管理局对医疗器械的基于风险的分类,以及510(k)上市前通知作为进入市场的主要监管机制。它还强调了美国食品药品监督管理局的关键指导文件,并鼓励在适当的时候尽早与美国食品药品管理局接触。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
0
审稿时长
13 weeks
期刊最新文献
Close female friendships and knowledge of recommended abortion methods in Nigeria and the Democratic Republic of the Congo among a representative sample of reproductive-aged women. Preferences for pre-exposure prophylaxis delivery among HIV-negative pregnant and breastfeeding women in Zambia: evidence from a discrete choice experiment. Achieving HIV epidemic control through accelerating efforts to expand access to pre-exposure prophylaxis for people who inject drugs. Editorial: Environmental impacts on women's health disparities and reproductive health: advancing environmental health equity in clinical and public health practice. Sexual and reproductive health literacy and its associated factors among adolescents in Harar town public high schools, Harari, Ethiopia, 2023: a multicenter cross-sectional study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1